ATENOLOL

SynDRA canonical compound SYN0000095 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	ADRB1 \| ADRB2 \| LTF \| PLA2G2E
Mechanism of action	adrenergic receptor antagonist
Indication	angina pectoris \| hypertension
Disease area	cardiology

All known targets

ADRB1
ADRB2
ADORA3
Adrb2
Htr1a
LTF
PLA2G2E

Mechanisms of action (all sources)

ADRB1 ANTAGONIST
Beta-1 adrenergic receptor antagonist
ADRB2 ANTAGONIST
adrenergic receptor antagonist

Bioactivity evidence (ChEMBL activities table — not curator-asserted)

Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)

ADRA1B

Drug classes

Adrenergic beta-Antagonists
beta-Adrenergic Blocker
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-1 Receptor Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Cardiovascular Agents
Neurotransmitter Agents
Peripheral Nervous System Agents
Sympatholytics

ATC classes

C07A · BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND THIAZIDES
BETA BLOCKING AGENTS AND OTHER DIURETICS
BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS
BETA BLOCKING AGENTS, OTHER COMBINATIONS

Cross-references

PubChem CID: 2249
ChEMBL: CHEMBL24
DrugBank: DB00335
ChEBI: CHEBI:55352
KEGG: D00235
RxNorm: 1202
Wikipedia: Atenolol
TTD: D01UXC
LINCS BRD: BRD-A20239487

Synonyms

Reported adverse events

Bradycardia
Depression
Dizziness
Nausea
Hypotension
Bronchospasm
Fatigue
Vertigo
Lethargy
Arrhythmia
Death
Peyronie's disease

Look up ATENOLOL in the interactive SynDRA portal →